Literature DB >> 12381701

First clinical trials of endostatin yield lukewarm results.

Renee Twombly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12381701     DOI： 10.1093/jnci/94.20.1520

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

1.  The use of GEM models for experimental cancer therapeutics.

Authors:  Aarthi Gopinathan; David A Tuveson
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

2.  Microenvironmental Heterogeneity Among Triple-Negative Breast Cancer Subtypes and the Promise of Precision Medicine.

Authors:  Lior Z Braunstein; Nadeem Riaz
Journal:  J Natl Cancer Inst       Date:  2020-07-01       Impact factor: 13.506

3.  Tumor angiogenesis: insights and innovations.

Authors:  Fernando Nussenbaum; Ira M Herman
Journal:  J Oncol       Date:  2010-04-26       Impact factor: 4.375

Review 4.  Glioma angiogenesis: Towards novel RNA therapeutics.

Authors:  Thomas Würdinger; Bakhos A Tannous
Journal:  Cell Adh Migr       Date:  2009-04-22       Impact factor: 3.405

Review 5.  Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.

Authors:  Amit Walia; Jessica F Yang; Yu-Hui Huang; Mark I Rosenblatt; Jin-Hong Chang; Dimitri T Azar
Journal:  Biochim Biophys Acta       Date:  2015-09-12

6.  Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis.

Authors:  Xu Hong; Lu Lei; Rickard Glas
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.